Amgen stock after-hours at EUR 372.85: minus 0.08 percent versus prior close
Published on 09/30/2026 at 18:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock was at EUR 372.85 after-hours at 6:48 p.m. CEST on September 30, 2026, according to Lang & Schwarz. The price was down 0.08 percent versus the prior close of EUR 373.15 at Lang & Schwarz.
Trading day in Frankfurt
The after-hours price was EUR 372.85 at the stated time. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Amgen stock.
Phase 3 study reaches primary endpoint
In a September 22, 2026 release, Amgen said its Phase 3 OASIZ 301 study of dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity met its primary endpoint. The company reported statistically significant and clinically meaningful improvement at Week 48, measured by the EULAR Sjögren's Syndrome Disease Activity Index. Improvements were observed as early as Week 4 and sustained through Week 48. Amgen said detailed data are planned for presentation at an upcoming medical meeting, while the OASIZ 303 study is expected to complete in the fourth quarter of 2026.
IMDELLTRA monitoring update
Amgen said in a September 14, 2026 investor-relations release that the U.S. Food and Drug Administration approved an update to IMDELLTRA prescribing information. The company said recommended monitoring for the first two doses was reduced to 6 to 8 hours from 22 to 24 hours in an appropriate healthcare setting.
